Skip to main content
. Author manuscript; available in PMC: 2022 Jan 29.
Published in final edited form as: Clin Cancer Res. 2019 Dec 23;26(6):1486–1496. doi: 10.1158/1078-0432.CCR-19-2478

Figure 5.

Figure 5.

Everolimus causes tumor regression and inhibits progression of mammary DCIS in MMTV/neu mouse. A, Experimental scheme for short-term everolimus treatment: 13-weeks old female MMTV/neu mice were treated with vehicle control or everolimus for one week. The mice were terminated 4 weeks later. B, Tumor images were captured at the termination of the experiment. C, Whole-mount stereo micrographs of representative mammary glands were acquired with a 0.75X or 5X objective. Scale bars: 250 μm or 1000 μm. D, H&E staining of representative mammary glands at the termination. Scale bars: 25 μm for 20X magnification or 500 μm for 4X magnification. E, The invasive percentage was calculated by No. IDC / No. of (DCIS and IDC) X 100. Data are shown as means ± SEM. **p<0.01 represents the comparison between control vehicle and everolimus treatment groups, t-test.